Findings

What do systematic reviews say?

628 questions · 651 findings · 39 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 167 · 25.7%GRADE not reported 47 · 7.2%Very low 80 · 12.3%Low 139 · 21.4%Moderate 174 · 26.7%High 44 · 6.8%

Clarithromycin vs placebo

Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Moderate

Acyclovir vs placebo, vitamins, or no treatment

Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 141 participants
Moderate

Acyclovir vs placebo, vitamins, or no treatment

The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea

Acyclovir probably leads to lower proportion of participants with resolution of itch within 2 weeks,… compared with placebo, vitamins, or no treatment (moderate certainty).

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
RR 0.34 [0.12, 0.94]
1 study · 21 participants
Moderate

Acyclovir vs placebo, vitamins, or no treatment

Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acyclovir vs placebo, vitamins, or no treatment

The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea

Acyclovir probably leads to higher the proportion of participants with good or excellent rash… compared with placebo, vitamins, or no treatment (moderate certainty).

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
RR 2.45 [1.33, 4.53]
3 studies · 141 participants
Moderate

Acyclovir vs placebo, vitamins, or no treatment

Minor adverse events not leading to withdrawal of treatment · pityriasis rosea

Acyclovir showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo, vitamins, or no treatment (moderate certainty).

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7.02]
3 studies · 141 participants
Moderate

Clarithromycin vs placebo

The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea

Clarithromycin showed no clear difference in the proportion of participants with resolution of itch within 2… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
RR 0.84 [0.47, 1.52]
1 study · 28 participants
Moderate

Clarithromycin vs placebo

Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Clarithromycin vs placebo

The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea

Clarithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
RR 1.13 [0.89, 1.44]
1 study · 60 participants
Moderate

Clarithromycin vs placebo

Minor adverse events not leading to withdrawal of treatment · pityriasis rosea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Erythromycin vs placebo

The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Erythromycin vs placebo

Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Moderate

Erythromycin vs placebo

The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for pityriasis rosea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Biotin vs placebo

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 39 participants
Very low

Biotin vs placebo

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 39 participants
GRADE not reported

Biotin vs placebo

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Proprietary products vs placebo

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 166 participants
Very low

Proprietary products vs placebo

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 166 participants
Very low

Proprietary products vs placebo

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile seborrhoeic dermatitis (including cradle cap) 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rifampicin vs placebo

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis

The review found no eligible studies for this question.

1 finding from 1 review

Antistreptococcal interventions for guttate and chronic plaque psoriasis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found